Skip to main content
Go to homepage
Akron Children's Hospital > For Families & Patients > Research > Pediatric Clinical Studies > Open Clinical Studies

PBTC 039 - Peginterferon Alfa-2b in Treating Younger Patients With Craniopharyngioma That is Recurrent or Cannot Be Removed By Surgery

Peginterferon Alfa-2b in Treating Younger Patients With Craniopharyngioma

Description:

For complete information, please visit the study on clinicaltrials.gov

This study is being done in collaboration with Cincinnati Children's Hospital.

Interested in participating?
We are currently recruiting
Full IRB Study Title:
PBTC-039: Phase II Study of Peginterferon alfa-2b (PEGIntron) for Pediatric Patients with Un-resectable or Recurrent Craniopharyngioma - Cincinnati
IRB Study ID:
141110
If you are interested in this study or have questions about your child's eligibility, please contact:
Rebecca D. Considine Research Institute, 330-543-3193 or email research@akronchildrens.org
Lead Investigator
Steven Kuerbitz, MD

Director, Divisional Research and Stem Cell Transplantation; Pediatric Hematologist-Oncologist
Showers Family Center for Childhood Cancer and Blood DisordersPediatric Stem Cell Transplant Program

Starting Locations:
Legal:
About Akron Children's

While we are ranked among the best children's hospitals in the country, it's our compassionate approach to treatment that makes us truly exceptional. Through a combination of revolutionary treatments and extraordinary patient experiences, our care does more than heal. It brings the entire family together for emotional support and understanding across multiple locations to reach you in the community where you live. Learn more...

Akron Children's Hospital
One Perkins Square, Akron, Ohio 44308-1062
330-543-1000 • webmaster@akronchildrens.org
An Equal Opportunity Employer
Copyright © 2018, Akron Children's Hospital. All Rights Reserved.
  • Voted Best Doctors 2017-18
  • Magnet Recongnition
  • U.S. News Best Children's Hospitals 2015-2016